Another alpha article - sure it will be below 4 tomorrow
Dipyridamole is generic for persantine. There is not a combo product currently on the market, but what I was getting at is that by first glance, you can mimic the formulation by using generic glucocorticoids, prednisolone included in combo with persantine and adjust dosing based on kinetics.
Personally, I hate when biotechs aren't inventive and basically just come out with a modified product that is already on the market and in the case of Exalgo, charge a 7500% increase in cost. There's a lot of drugs I personally feel I could combo up that are already FDA approved, but it only drives up health care costs.
I'm still long TSRX, but recently sold my stake to move more into ARNA. ARNA seems to be having good support above $3 on lower volume. An analyst recently affirmed what I also believed and stated odds are 80% approval for ARNA and most believe a price target on approval of $10-12 per share. Trading at $3.07 now, that's nice potential even if you buy in now. I'll likely take some off the table along the way and invest back into TSRX. Only invest what you're willing to lose though!